Incyte to Acquire Vega Therapeutics for Up to $2 Billion, Adding Phase 3 Bleeding Disorder Drug
INCY sits 53% above its 52-week low of $66.74.
Summary
Incyte announced the acquisition of Vega Therapeutics for $1.25 billion upfront, with up to $750 million in additional sales milestones, totaling up to $2.0 billion. This strategic move adds VGA039, a novel Phase 3 monoclonal antibody for von Willebrand disease, to Incyte's hematology portfolio. VGA039 holds multiple FDA designations, including Breakthrough Therapy, and has the potential to be the first subcutaneous prophylactic therapy for VWD, addressing a significant unmet need. The acquisition is expected to result in an R&D charge of approximately $1.25 billion in Q3 2026. This material investment in a late-stage asset aligns with Incyte's recent positive pipeline and regulatory developments. Incyte will host an analyst call today at 8:00 a.m. ET to discuss the deal, which is expected to close in Q3 2026.
At the time of this announcement, INCY was trading at $102.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20.5B. The 52-week trading range was $66.74 to $112.29. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.